Transcriptional regulation of oct4 in human bone marrow mesenchymal stem cells.
Wei X., Shen CY.
Laboratory Study, published in Stem Cells Dev (2010) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Stem Cells Dev (2010)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 20594032
- DOI
- 10.1089/scd.2010.0069
Abstract (original English)
Oct4 is a key transcription factor to maintain self-renewal and undifferentiated state of embryonic stem cells. Site 2A located between -2,546 and -2,530 bp and site 2B between -2,500 and -2,486 bp of human Oct4 gene were shown to be sufficient for inducing Oct4 gene expression in embryonic stem cells. Site 2B contains octamer element capable of binding to factor Oct4 and sox element capable of binding to factor Sox2. So far, little is known about the molecular mechanisms for the control of growth and differentiation of adult stem cells including bone marrow-derived mesenchymal stem cells (BM-MSCs), and it is important to understand how Oct4 expression is regulated in BM-MSCs. This study showed that Oct4 and Sox2 genes were expressed in undifferentiated BM-MSCs and BM-MSCs on day 7 but not on days 14 and 21 following osteogenic induction. Site 2A of Oct4 gene, not site 2B, activated the expression of reporter genes luciferase and enhanced green fluorescent protein in undifferentiated BM-MSCs but not in BM-MSCs following osteogenic differentiation. These data demonstrate that site 2A is sufficient for inducing the expression of Oct4 gene in BM-MSCs, and site 2B is not required. Electrophoretic mobility shift assay showed the 2 shifted bands with site 2B probe and the addition of Oct4 and Sox2 antibodies did not supershift these 2 bands. As probes containing mutated octamer and s
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.